Skip to content
Search

Latest Stories

IMF approves fund increase to support pandemic-hit nations

THE International Monetary Fund has approved a $650 billion (£466bn) allocation to its resources pool to help economically vulnerable countries battling the coronavirus pandemic.

The 190-nation lending institution said on Monday (2) that its board of governors approved the expansion of its reserves known as Special Drawing Rights (SDRs), the largest increase in the IMF's history.


This is a historic decision ... and a shot in the arm for the global economy at a time of unprecedented crisis, IMF managing director Kristalina Georgieva said.

The general allocation of SDRs will become effective on August 23.

The new reserves will be credited to IMF member nations in proportion to their existing quotas with the agency. Nearly $275bn (£197bn) of the new allocation will go to the world's poorer countries, the IMF said.

The move is aimed at supporting countries that are struggling to emerge from the pandemic crisis.

The agency also said that it is looking into ways richer nations could voluntarily channel SDRs to poorer countries.

Earlier, the big boost in IMF resources was rejected by the former US president Donald Trump’s administration, but after president Joe Biden took office in January, treasury secretary Janet Yellen supported the proposal.

Many Republican members of Congress objected to the SDR increase, arguing that the expanded IMF resources would benefit US adversaries such as China, Russia and Iran.

However, the proposal was strongly supported by international relief agencies.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less